mGluR2 NAM / Addex, IRCCS Neuromed - LARVOL DELTA

Addex mGlu2 NAM Cognition Program Receives €4 Million Grant (GlobeNewswire) - " Addex Therapeutics...announced that it has led a consortium which has been awarded a €4 million Eurostars grant to support its metabotropic glutamate 2 (mGlu2) receptor negative allosteric modulator (NAM) program for mild neurocognitive disorder (mNCD). The project, named COGNI+, has been awarded the grant to deliver clinical candidates ready for IND enabling studies. The consortium includes Naason Science (South Korea), BioAxis Research (Netherlands), Pharmidex Pharmaceutical Services (UK) and Stichting Radboud Universiteit (Netherlands)....'As a reminder, our ADX71149 epilepsy program is on track to report Phase 2 data in Q2 2024 and we continue to make solid progress toward achieving other strategic objectives, including securing industry partners for certain programs."

Financing • P2 data • Alzheimer's Disease • CNS Disorders • Epilepsy • Parkinson's Disease